Propranololo ed emangiomi

Translated title of the contribution: Propranolol and haemangiomas

Irene Berti, Matteo Pavan, Giulia Paloni, Cristina Bibalo, Federico Marchetti, Alessandro Ventura

Research output: Contribution to journalArticle

Abstract

Infantile Haemangiomas (IE) are common benign tumours, affecting around 10% of the new borns. Natural history goes towards a spontaneous regression in most cases, although in long times (years) and sometimes with some imperfect outcome. Propranolol has been recently proposed as a very effective treatment for IE, without relevant side effects. The number of children treated is increasing very quickly, but currently there are neither uniform guidelines nor shared protocols. Basing on available data it can be said that propranolol is very safe and the current recommendations for cardiovascular monitoring may probably be simplified. For very superficial lesions and at the very beginning, topical timolol can be used successfully.

Translated title of the contributionPropranolol and haemangiomas
Original languageItalian
Pages (from-to)651-657
Number of pages7
JournalMedico e Bambino
Volume32
Issue number10
Publication statusPublished - Dec 2013

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Propranolol and haemangiomas'. Together they form a unique fingerprint.

  • Cite this

    Berti, I., Pavan, M., Paloni, G., Bibalo, C., Marchetti, F., & Ventura, A. (2013). Propranololo ed emangiomi. Medico e Bambino, 32(10), 651-657.